Immunic Stock Buy Hold or Sell Recommendation
| IMUX Stock | USD 1.24 0.01 0.81% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immunic is 'Strong Sell'. Macroaxis provides Immunic buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Immunic positions. The advice algorithm takes into account all of Immunic's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Immunic's buy or sell advice are summarized below:
Real Value 4.33 | Target Price 13.75 | Hype Value 1.25 | Market Value 1.24 | Naive Value 1.16 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Immunic given historical horizon and risk tolerance towards Immunic. When Macroaxis issues a 'buy' or 'sell' recommendation for Immunic, the advice is generated through an automated system that utilizes algorithms and statistical models.
Immunic |
Execute Immunic Buy or Sell Advice
The Immunic recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunic. Macroaxis does not own or have any residual interests in Immunic or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunic's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunic Trading Alerts and Improvement Suggestions
| Immunic may become a speculative penny stock | |
| Immunic had very high historical volatility over the last 90 days | |
| Net Loss for the year was (93.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (70.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Immunic Upgraded by StockNews.com to Hold - MarketBeat |
Immunic Returns Distribution Density
The distribution of Immunic's historical returns is an attempt to chart the uncertainty of Immunic's future price movements. The chart of the probability distribution of Immunic daily returns describes the distribution of returns around its average expected value. We use Immunic price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunic returns is essential to provide solid investment advice for Immunic.
| Mean Return | 0.20 | Value At Risk | -6.54 | Potential Upside | 7.75 | Standard Deviation | 4.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunic historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immunic Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sierra Summit Advisors Llc | 2023-12-31 | 324.8 K | Cowen And Company, Llc | 2023-12-31 | 317.1 K | Soleus Capital Management, L.p. | 2023-12-31 | 300 K | Innovis Asset Management Llc | 2023-09-30 | 272.5 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 238.7 K | Northern Trust Corp | 2023-12-31 | 164.4 K | Two Sigma Advisers, Llc | 2023-12-31 | 147.4 K | State Street Corporation | 2023-12-31 | 125.8 K | Two Sigma Investments Llc | 2023-12-31 | 116.5 K | Rtw Investments, Llc | 2023-12-31 | 4.3 M | Gratus Capital Llc | 2023-12-31 | 1.9 M |
Immunic Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 16.3M | 98.1M | (40.6M) | 19.9M | (60.1M) | (57.1M) | |
| Free Cash Flow | (28.6M) | (46.3M) | (83.3M) | (65.3M) | (71.2M) | (67.6M) | |
| Depreciation | 50K | 39K | 85K | 77K | 111K | 105.5K | |
| Other Non Cash Items | 1.5M | (2.5M) | 8.6M | 37.7M | 1.3M | 1.3M | |
| Capital Expenditures | 55K | 146K | 67K | 112K | 334K | 496.2K | |
| Net Income | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (88.9M) | |
| End Period Cash Flow | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
| Change To Netincome | 7.7M | 219K | 18.9M | 45.7M | 52.5M | 55.1M | |
| Investments | 10.5M | (146K) | (67K) | (9.7M) | 9.5M | 9.9M |
Immunic Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunic or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunic's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunic stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.08 | |
β | Beta against NYSE Composite | 1.30 | |
σ | Overall volatility | 4.35 | |
Ir | Information ratio | 0.03 |
Immunic Volatility Alert
Immunic exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunic's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immunic Fundamentals Vs Peers
Comparing Immunic's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunic's direct or indirect competition across all of the common fundamentals between Immunic and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunic or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunic's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immunic to competition |
| Fundamentals | Immunic | Peer Average |
| Return On Equity | -1.31 | -0.31 |
| Return On Asset | -0.68 | -0.14 |
| Current Valuation | 66.17 M | 16.62 B |
| Shares Outstanding | 89.93 M | 571.82 M |
| Shares Owned By Insiders | 7.72 % | 10.09 % |
| Shares Owned By Institutions | 58.08 % | 39.21 % |
| Number Of Shares Shorted | 3.03 M | 4.71 M |
| Price To Earning | (6.65) X | 28.72 X |
| Price To Book | 4.48 X | 9.51 X |
| EBITDA | (99.11 M) | 3.9 B |
| Net Income | (93.61 M) | 570.98 M |
| Cash And Equivalents | 72.77 M | 2.7 B |
| Cash Per Share | 1.85 X | 5.01 X |
| Total Debt | 1.33 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 7.53 X | 2.16 X |
| Book Value Per Share | 0.64 X | 1.93 K |
| Cash Flow From Operations | (70.83 M) | 971.22 M |
| Short Ratio | 5.23 X | 4.00 X |
| Earnings Per Share | (2.11) X | 3.12 X |
| Price To Earnings To Growth | (0.03) X | 4.89 X |
| Target Price | 11.5 | |
| Number Of Employees | 77 | 18.84 K |
| Beta | 1.95 | -0.15 |
| Market Capitalization | 111.51 M | 19.03 B |
| Total Asset | 54.3 M | 29.47 B |
| Retained Earnings | (410.89 M) | 9.33 B |
| Working Capital | 27.8 M | 1.48 B |
| Current Asset | 32.33 M | 9.34 B |
| Current Liabilities | 4.73 M | 7.9 B |
| Net Asset | 54.3 M |
Note: Disposition of 30000 shares by Toernsen Monika Maria of Immunic at 4.3 subject to Rule 16b-3 [view details]
Immunic Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immunic . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immunic Buy or Sell Advice
When is the right time to buy or sell Immunic? Buying financial instruments such as Immunic Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 584K | 1.6M | 1.3M | 955.9K | Total Assets | 139.1M | 127.8M | 54.3M | 81.3M |
Use Investing Ideas to Build Portfolios
In addition to having Immunic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Immunic Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.